Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
A new trial from China published in the BMJ journal revealed that telesurgery was non-inferior to standard local robotic ...
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today provided recent business highlights and reported ...
Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...
Background Motor and cognitive dysfunctions are common and disabling features in multiple sclerosis (MS) that remain challenging to treat. Here, we aimed to explore the effect of exergames as a ...
As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive monitoring protocols and the potential benefits of streamlined, less intensive ...
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM ESTCompany ParticipantsJohn Butler ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results